A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Inclusion Criteria:

- Is a pre-menopausal female, 18-47

- Subject has a history of at least 3 regular menstrual cycles in which menorrhagia
(heavy bleeding) is due to uterine fibroids

- Confirmed uterine fibroid(s) at screening

- Visit 1 historical pictorial blood loss assessment chart of >120 mL of blood loss, to
ensure subjects have a menstrual blood loss of at least 80 mL by Alkaline Hematin
Assay (during the baseline assessment period).

- A Body Mass Index (BMI) between 18 and 45 inclusive

Exclusion Criteria:

- Subject is pregnant or lactating or is attempting or expecting to become pregnant
during the entire study period

- Received an investigational drug in the 30 days prior to the screening for this study

- Has an intrauterine device in place

- Observation or history of abnormal endometrial biopsy including the presence of
endometrial intraepithelial neoplasia

- Subjects with abnormally high liver enzymes or liver disease.